Top ▲

Androgen receptor

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 628

Nomenclature: Androgen receptor

Systematic Nomenclature: NR3C4

Family: 3C. 3-Ketosteroid receptors

Contents:

Gene and Protein Information Click here for help
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 920 Xq12 AR androgen receptor 7,19
Mouse 899 X 42.82 cM Ar androgen receptor 21,56
Rat 902 Xq22 Ar androgen receptor 81
Previous and Unofficial Names Click here for help
dihydrotestosterone receptor | AR | Andr | nuclear receptor subfamily 3 group C member 4 | AIS | DHTR | HUMARA | HYSP1
Database Links Click here for help
Alphafold P10275 (Hs), P19091 (Mm), P15207 (Rn)
CATH/Gene3D 2.130.10.10
ChEMBL Target CHEMBL1871 (Hs), CHEMBL3056 (Mm), CHEMBL3072 (Rn)
DrugBank Target P10275 (Hs)
Ensembl Gene ENSG00000169083 (Hs), ENSMUSG00000046532 (Mm), ENSRNOG00000005639 (Rn)
Entrez Gene 367 (Hs), 11835 (Mm), 24208 (Rn)
Human Protein Atlas ENSG00000169083 (Hs)
KEGG Gene hsa:367 (Hs), mmu:11835 (Mm), rno:24208 (Rn)
OMIM 313700 (Hs)
Orphanet ORPHA132285 (Hs)
Pharos P10275 (Hs)
RefSeq Nucleotide NM_000044 (Hs), NM_001011645 (Hs), NM_013476 (Mm), NM_012502 (Rn)
RefSeq Protein NP_000035 (Hs), NP_001011645 (Hs), NP_038504 (Mm), NP_036634 (Rn)
SynPHARM 80692 (in complex with andarine)
6569 (in complex with cyproterone acetate)
6559 (in complex with dihydrotestosterone)
14316 (in complex with dihydrotestosterone)
14315 (in complex with hydroxyflutamide)
14314 (in complex with methyltrienolone)
8029 (in complex with [3H]methyltrienolone)
UniProtKB P10275 (Hs), P19091 (Mm), P15207 (Rn)
Wikipedia AR (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Androgen receptor- ligand binding domain
PDB Id:  3L3X
Ligand:  dihydrotestosterone   This ligand is endogenous
Resolution:  1.55Å
Species:  Human
References:  103
Natural/Endogenous Ligands Click here for help
dihydrotestosterone
testosterone
Comments: Dihydrotestosterone has greater potency than testosterone
Rank order of potency (Human)
dihydrotestosterone > testosterone

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
dihydrotestosterone Small molecule or natural product Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 9.3 pKd 84
⤷ pKd 9.3 (Kd 5x10-10 M) [84]
testosterone propionate Small molecule or natural product Approved drug Primary target of this compound Hs Agonist 9.6 pKi 59
⤷ pKi 9.6 (Ki 2.5x10-10 M) [59]
andarine Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Agonist 8.4 pKi 66
⤷ pKi 8.4 (Ki 4x10-9 M) [66]
fluoxymesterone Small molecule or natural product Approved drug Primary target of this compound Hs Agonist 8.2 pKi 35
⤷ pKi 8.2 (Ki 5.7x10-9 M) [35]
danazol Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Rn Agonist 8.0 pKi 10
⤷ pKi 8.0 (Ki 1x10-8 M) [10]
methyltestosterone Small molecule or natural product Primary target of this compound Hs Full agonist 9.7 pEC50 2
⤷ pEC50 9.7 (EC50 2.2x10-10 M) Androgen receptor promoter activity in luciferase reporter assay [2]
Description: 22Rv1 human prostate cells transfected with hAR and luciferase reporter plasmid driven by the androgen response element.
GSK2881078 Small molecule or natural product Hs Agonist 8.4 pEC50 104
⤷ pEC50 8.4 (EC50 3.99x10-9 M) [104]
Description: Measuring stimulation of reporter gene transactivation in PC3(AR)2 cells.
methyltrienolone Small molecule or natural product Ligand has a PDB structure Hs Agonist <5.0 pEC50 92
⤷ pEC50 <5.0 (EC50 >1x10-5 M) [92]
mibolerone Small molecule or natural product Hs Agonist 9.0 pIC50 27
⤷ pIC50 9.0 (IC50 1.1x10-9 M) [27]
mibolerone Small molecule or natural product Rn Agonist 8.8 pIC50 19
⤷ pIC50 8.8 [19]
dihydrotestosterone Small molecule or natural product Ligand is endogenous in the given species Ligand has a PDB structure Rn Agonist 8.6 pIC50 19
⤷ pIC50 8.6 [19]
androstenedione Small molecule or natural product Ligand has a PDB structure Rn Agonist 8.6 pIC50 19
⤷ pIC50 8.6 [19]
methyltrienolone Small molecule or natural product Ligand has a PDB structure Rn Agonist 8.5 pIC50 19
⤷ pIC50 8.5 [19]
testosterone Small molecule or natural product Approved drug Ligand is endogenous in the given species Ligand has a PDB structure Rn Agonist 7.8 pIC50 19
⤷ pIC50 7.8 [19]
stanozolol Small molecule or natural product Approved drug Rn Agonist 7.7 pIC50 4
⤷ pIC50 7.7 (IC50 2.2x10-8 M) [4]
Description: Measured in a DrugMatrix in vitro androgen receptor radioligand binding assay using [3H] mibolerone as tracer.
[3H]dihydrotestosterone Small molecule or natural product Ligand is labelled Ligand is radioactive Ligand has a PDB structure Hs Agonist - -
⤷
[3H]mibolerone Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Agonist - -
⤷
[3H]methyltrienolone Small molecule or natural product Ligand is labelled Ligand is radioactive Ligand has a PDB structure Hs Agonist - -
⤷
dromostanolone propionate Small molecule or natural product Approved drug Primary target of this compound Hs Agonist - -
⤷
ethylestrenol Small molecule or natural product Approved drug Primary target of this compound Hs Agonist - -
⤷
nandrolone Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Agonist - -
⤷
View species-specific agonist tables
Agonist Comments
Combined treatment with drostanolone propionate and 5-fluoracil significantly increased the complete remission rate of induced mammary carcinomas in rats, compared to 5-fluoracil alone [83].
In a study comparing the competitive binding (displacement of [3H]methyltrienolone) of various anabolic steroids to the AR of skeletal muscle (rat and rabbit) and prostate tissue (rat), the binding of ethylestrenol was too low to determine its relative binding affinity [73].
A study by Krieg et al. (1976) examines the relative displaceable binding of nandrolone (aka 19-nortestosterone), testosterone and 5α-dihydrotestosterone to the rat androgen receptor [48].
Antagonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
mifepristone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 9.2 pKi 90
⤷ pKi 9.2 (Ki 6.5x10-10 M) [90]
darolutamide Small molecule or natural product Approved drug Rn Antagonist 8.0 pKi 67
⤷ pKi 8.0 (Ki 1.1x10-8 M) [67]
Description: Binding affinity measured in competition with [3H]mibolerone using wtAR isolated from rat ventral prostates.
cyproterone acetate Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Antagonist 7.8 pKi 32
⤷ pKi 7.8 (Ki 1.4x10-8 M) [32]
bicalutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 7.7 pKi 46
⤷ pKi 7.7 (Ki 1.9x10-8 M) [46]
clascoterone Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 7.4 pKi 20
⤷ pKi 7.4 (Ki 4x10-8 M) [20]
Description: Determined by measuring displacement of [3H]methyltrienolone from androgen receptor in human prostate cancer cells.
enzalutamide Small molecule or natural product Approved drug Rn Antagonist 7.1 pKi 67
⤷ pKi 7.1 (Ki 8.6x10-8 M) [67]
Description: Binding affinity measured in competition with [3H]mibolerone using wtAR isolated from rat ventral prostates.
apalutamide Small molecule or natural product Approved drug Rn Antagonist 7.0 pKi 67
⤷ pKi 7.0 (Ki 9.3x10-8 M) [67]
Description: Binding affinity measured in competition with [3H]mibolerone using wtAR isolated from rat ventral prostates.
flutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 5.4 pKi 91
⤷ pKi 5.4 (Ki 3.7x10-6 M) Displacement of 3[H] testosterone from wild-type androgen receptors [91]
hydroxyflutamide Small molecule or natural product Ligand has a PDB structure Hs Antagonist 6.6 pEC50 92
⤷ pEC50 6.6 (EC50 2.54x10-7 M) [92]
darolutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 7.6 pIC50 67
⤷ pIC50 7.6 (IC50 2.6x10-8 M) [67]
Description: Antagonism of testosterone-induced activation of wtAR determined using AR-HEK293 cells and a luciferase reporter system.
pruxelutamide Small molecule or natural product Hs Antagonist 7.5 pIC50 102
⤷ pIC50 7.5 (IC50 3.2x10-8 M) [102]
Description: Determined in an AR competitive binding assay.
JNJ-63576253 Small molecule or natural product Hs Antagonist 7.3 – 7.4 pIC50 101
⤷ pIC50 7.4 (IC50 3.7x10-8 M) [101]
Description: Antagonism in LNCaP cells with F877L mutated AR
pIC50 7.3 (IC50 5.4x10-8 M) [101]
Description: Antagonism in LNCaP cells with WT AR
PF0998425 Small molecule or natural product Hs Antagonist 7.1 – 7.5 pIC50 50
⤷ pIC50 7.1 – 7.5 [50]
ARD-69 Small molecule or natural product Hs Antagonist ~7.2 pIC50 29
⤷ pIC50 ~7.2 (IC50 ~5.9x10-8 M) [29]
Description: Based on the IC50
nilutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 7.1 – 7.1 pIC50 76
⤷ pIC50 7.1 – 7.1 (IC50 8.5x10-8 – 7.5x10-8 M) [76]
enzalutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 6.7 – 7.4 pIC50 67,86
⤷ pIC50 7.4 (IC50 3.6x10-8 M) [86]
pIC50 6.7 (IC50 2.19x10-7 M) [67]
Description: Antagonism of testosterone-induced activation of wtAR determined using AR-HEK293 cells and a luciferase reporter system.
apalutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 6.7 – 6.9 pIC50 41,67
⤷ pIC50 6.9 (IC50 1.22x10-7 M) [41]
pIC50 6.7 (IC50 2x10-7 M) [67]
Description: Antagonism of testosterone-induced activation of wtAR determined using AR-HEK293 cells and a luciferase reporter system..
galeterone Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 6.4 pIC50 34
⤷ pIC50 6.4 (IC50 3.84x10-7 M) [34]
bicalutamide Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 6.0 pIC50 41
⤷ pIC50 6.0 (IC50 1x10-6 M) [41]
bisphenol A Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 5.2 pIC50 61
⤷ pIC50 5.2 (IC50 5.9x10-6 M) [61]
PF-03882845 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.1 pIC50 9
⤷ pIC50 5.1 (IC50 8.91x10-6 M) [9]
ARD-266 Small molecule or natural product Hs Antagonist - - 33
⤷ [33]
View species-specific antagonist tables
Antagonist Comments
Enzalutamide antagonises testosterone-induced androgen-dependent gene transcription and nuclear translocation of the androgen receptor in human prostate LnCaP cells [28].
DNA Binding Click here for help
Structure:  Homodimer
HRE core sequence:  GGTACANNNTGTTCT
Response element:  GRE, Palindrome
DNA Binding Comments
NR3C1-4 receptors all bind to the same consensus sequence. Data indicate that sequences surrounding the response element may confer specificity to receptor binding.
Co-binding Partners Click here for help
Name Interaction Effect Reference
HMGB Physical, Functional DNA binding 6,88
Hsp90 Physical Cellular localization, protein stability 25,60
FKBP52 Physical Cellular Localization, Protein Stability, Development 99
Co-binding Partners Comments
FKBP52 (52 kDa FK506 binding protein) is a co-chaperone required for normal function of some, but not all steroid receptors. Elimination of FKBP52 in a mouse model reduces androgen receptor activity and yields a phenotype characteristic of partial androgen insensitivity syndrome (AIS). It is being tested as a therapeutic target in prostate cancer [99].
Main Co-regulators Click here for help
Name Activity Specific Ligand dependent AF-2 dependent Comments References
RNF14 Co-activator Yes Yes Yes 40,42,64
TGFB1I1 Co-activator Yes Yes Yes 23,63,65,97
RAN Co-activator Yes Yes Yes 36,97
SMARCD1 Co-activator - No - 87
CARM1 Co-activator - No - 58
NCOR1 Co-repressor - No - 13,75
NCOR2 Co-repressor - No - 13,75
NCOA2 Co-activator No Yes Yes Histone acetyl transferase, also a nucleating platform for recruitment of general coactivators (CBP, CARM1, p300) 26,43,96
NCOA4 Co-activator Yes Yes Yes Increases AR expression, protein stability, and nuclear translocation. 26,38,97
FHL2 Co-activator Yes Yes Yes Contains 4 1/2 LIM domains 11,68
NCOA3 Co-activator - No - 62
NCOA1 Co-activator - No - 62,70
MED1 Co-activator - No - 16
EP300 Co-activator - No - 22
KAT5 Co-activator - No - 24
UBE3A Co-activator - No - 45
KAT2B Co-activator - No - 72
CCND1 Co-repressor - No - This entry refers to the CCND1a variant 8
Main Co-regulators Comments
More than 100 nuclear receptor coregulators have been identified. Initially, some were described as specific to a single receptor. However, most, if not all, of the coregulators have been shown to regulate more than one receptor as well as other transcription factors. For a complete listing of coregulators and their nuclear receptor interactions, see NURSA. Listed above are some of the better characterized androgen receptor coregulators.
Main Target Genes Click here for help
Name Species Effect Technique Comments References
Pbsn Rat Activated Transient transfection 71
rsl Mouse Activated Transient transfection, EMSA 74
C3 Rat Activated Transient transfection, EMSA 82
human secretory component Human Activated Transient transfection, EMSA 31,89
KLK3 Human Activated ChIP, Transient transfection, EMSA, Footprint Also observed in rodents 15,100
transmembrane protease, serine 2 Human Activated ChIP, Transient transfection, Endogenous gene TMPRSS2-ERG fusion is the most common type of TMPRSS2 gene and ETS transcription factor fusion found in prostate cancer. 52,85,93
Tissue Distribution Click here for help
Kidney, liver, adrenal cortex and pituitary gland. N.B. This tissue distribution was also seen in rat and mouse
Expression level:  Low
Species:  Human
Technique:  Immunohistochemistry
References:  80
Bone marrow, mammary gland, muscle, prostate, stem cell, testis, preputial gland, scrotal skin, vagina
Expression level:  High
Species:  Rat
Technique:  Western blotting
References:  5
Functional Assays Click here for help
SHBG increase in liver - androgen treatment increases expression of sex hormone binding globulin in liver
Species:  Human
Tissue:  hepatocarcinoma cell line HepG2
Response measured:  SHBG secretion
References:  49
Anabolic action in muscle - treatment of castrated rats with AR ligands possessing anabolic activity results in increased muscle mass.
Species:  Rat
Tissue:  skeletal muscle
Response measured:  weight of the levator ani muscle
References:  98
Prostate weight and seminal vessicle weight - treatment castrated rats with AR ligands possessing androgenic activity results in increased weight of the prostate and seminal vesicles.
Species:  Rat
Tissue:  prostate, seminal vesicles
Response measured:  weight of prostate and seminal vesicles
References:  98
Physiological Consequences of Altering Gene Expression Click here for help
Insulin resistance - male mice lacking AR (-/y) display progressive reduced insulin sensitivity and impaired glucose tolerance
Species:  Mouse
Tissue: 
Technique:  targeted knock-out
References:  18,53-54
Infertility - male mice lacking expression of AR in the Sertoli cells display infertility with defective spermatogenesis and hypotestosteronemia
Species:  Mouse
Tissue: 
Technique:  targeted knock-out
References:  12
Impaired epididymis development
Species:  Mouse
Tissue:  Epididymis
Technique:  Targeted AR knock-in (SPARKI)
References:  44
ARv567es Mouse. Probasin (Pb) promoter-driven ARv567es transgenic mouse (Pb-ARv567es) displayed a phenotype of epithelial hyperplasia by 16 weeks and invasive adenocarcinoma was evident by 1 year of age.
Species:  Human
Tissue: 
Technique:  Transgenic mouse
References:  55
AR3Tg Mouse. Transgenic mouse model (AR3Tg) with targeted expression of AR splice variant AR3 (AR-V7) in prostate epithelium displayed a phenotype of prostatic intraepithelial neoplasia (PIN) via modulation of several tumor-promoting autocrine/paracrine factors.
Species:  Mouse
Tissue: 
Technique:  Transgenic mouse
References:  77
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0005189 abnormal anogenital distance PMID: 5452809 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005189 abnormal anogenital distance PMID: 12370412 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0009642 abnormal blood homeostasis PMID: 16981011 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001259 abnormal body weight PMID: 12943692 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0000172 abnormal bone marrow cell number PMID: 9647203 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0008271 abnormal bone ossification PMID: 12370412 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0000662 abnormal branching of the mammary ductal tree PMID: 14676301 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0000130 abnormal cancellous bone morphology PMID: 12370412 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0002662 abnormal cauda epididymis morphology PMID: 18356274 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0009697 abnormal copulation PMID: 18356274 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0002661 abnormal corpus epididymis morphology PMID: 18356274 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0000245 abnormal erythropoiesis PMID: 9647203 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009199 abnormal external male genitalia morphology PMID: 12370412 
Artm2Ska|Gli1+|Gli1tm3(cre/ERT2)Alj Artm2Ska/Y,Gli1tm3(cre/ERT2)Alj/Gli1+
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:88064  MGI:95727  MP:0009199 abnormal external male genitalia morphology PMID: 19282366 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009115 abnormal fat cell morphology PMID: 12370412  15919793 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0001119 abnormal female reproductive system morphology PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0001119 abnormal female reproductive system morphology PMID: 5452809 
Artm2Ska|Gli1+|Gli1tm3(cre/ERT2)Alj Artm2Ska/Y,Gli1tm3(cre/ERT2)Alj/Gli1+
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:88064  MGI:95727  MP:0003553 abnormal foreskin morphology PMID: 19282366 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0001929 abnormal gametogenesis PMID: 5452809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0005149 abnormal gubernaculum morphology PMID: 10319319 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0003921 abnormal heart left ventricle morphology PMID: 15961403 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001764 abnormal homeostasis PMID: 12370412 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001882 abnormal lactation PMID: 14676301 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0002786 abnormal Leydig cell morphology PMID: 5452809 
ArTfm ArTfm/Y
Not Specified		 MGI:88064  MP:0002786 abnormal Leydig cell morphology PMID: 11090455 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0002786 abnormal Leydig cell morphology PMID: 15919750 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002786 abnormal Leydig cell morphology PMID: 12370412 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/0
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0002786 abnormal Leydig cell morphology PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/0
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0002786 abnormal Leydig cell morphology PMID: 19574395 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0000133 abnormal long bone metaphysis morphology PMID: 12370412 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0001145 abnormal male reproductive system morphology PMID: 7954809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0001145 abnormal male reproductive system morphology PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0001145 abnormal male reproductive system morphology PMID: 5452809 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001145 abnormal male reproductive system morphology PMID: 14745012 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001145 abnormal male reproductive system morphology PMID: 16326839 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0000627 abnormal mammary gland morphology PMID: 14676301 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001930 abnormal meiosis PMID: 17142319 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0001930 abnormal meiosis PMID: 17142319 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0004145 abnormal muscle electrophysiology PMID: 16981011 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0008250 abnormal myeloid leukocyte morphology PMID: 9647203 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0000278 abnormal myocardial fiber morphology PMID: 15961403 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001382 abnormal nursing PMID: 14676301 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0005187 abnormal penis morphology PMID: 12943692 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0006420 abnormal peritubular myoid cell morphology PMID: 14745012 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001731 abnormal postnatal growth PMID: 14745012 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0001163 abnormal prostate gland anterior lobe morphology PMID: 17317769 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0001168 abnormal prostate gland epithelium morphology PMID: 17317769 
Artm1Chc|Tg(Pbsn-cre)4Prb Artm1Chc/Y,Tg(Pbsn-cre)4Prb/0
involves: 129S/SvEv * C57BL/6 * DBA/2		 MGI:2388169  MGI:88064  MP:0001168 abnormal prostate gland epithelium morphology PMID: 17652515 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0001158 abnormal prostate gland morphology PMID: 17317769 
Artm1Chc|Tg(Pbsn-cre)4Prb Artm1Chc/Y,Tg(Pbsn-cre)4Prb/0
involves: 129S/SvEv * C57BL/6 * DBA/2		 MGI:2388169  MGI:88064  MP:0001158 abnormal prostate gland morphology PMID: 17652515 
Artm2Ska|Gli1+|Gli1tm3(cre/ERT2)Alj Artm2Ska/Y,Gli1tm3(cre/ERT2)Alj/Gli1+
involves: 129S6/SvEvTac * C57BL/6 * CBA		 MGI:88064  MGI:95727  MP:0003936 abnormal reproductive system development PMID: 19282366 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001919 abnormal reproductive system physiology PMID: 12943692 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002669 abnormal scrotum morphology PMID: 12370412 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0002212 abnormal secondary sex determination PMID: 7954809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0002212 abnormal secondary sex determination PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0002212 abnormal secondary sex determination PMID: 5452809 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0002212 abnormal secondary sex determination PMID: 14745012 
ArTfm-Jms ArTfm-Jms/Y
C57BL/6JJms		 MGI:88064  MP:0002212 abnormal secondary sex determination PMID: 7967466 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0002059 abnormal seminal vesicle morphology PMID: 17317769 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0002059 abnormal seminal vesicle morphology PMID: 18356274 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 18401008 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 16981011 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 17142319 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 15107499  17142319 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 17142319 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0002216 abnormal seminiferous tubule morphology PMID: 18401008 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002784 abnormal Sertoli cell morphology PMID: 16400023 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002784 abnormal Sertoli cell morphology PMID: 12370412  17142319 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0003084 abnormal skeletal muscle fiber morphology PMID: 16981011 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0002557 abnormal social/conspecific interaction PMID: 5452809 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0006380 abnormal spermatid morphology PMID: 14745012 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0006379 abnormal spermatocyte morphology PMID: 14745012 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0006379 abnormal spermatocyte morphology PMID: 17142319 
ArTfm ArTfm/Y
Not Specified		 MGI:88064  MP:0001156 abnormal spermatogenesis PMID: 11090455 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001156 abnormal spermatogenesis PMID: 14745012 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001156 abnormal spermatogenesis PMID: 16400023 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001156 abnormal spermatogenesis PMID: 15107499 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/0
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0001156 abnormal spermatogenesis PMID: 19574395 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0006378 abnormal spermatogonia morphology PMID: 12370412 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0008892 abnormal sperm flagellum morphology PMID: 18356274 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0002673 abnormal sperm number PMID: 18356274 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0004543 abnormal sperm physiology PMID: 18356274 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000955 abnormal spinal cord morphology PMID: 16981011 
ArTfm ArTfm/Y
Not Specified		 MGI:88064  MP:0001146 abnormal testis morphology PMID: 11090455 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0001146 abnormal testis morphology PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0001146 abnormal testis morphology PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001146 abnormal testis morphology PMID: 16400023 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001146 abnormal testis morphology PMID: 16326839 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0001146 abnormal testis morphology PMID: 17317769 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/Tg(Abpa-cre)1Cmal
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0001146 abnormal testis morphology PMID: 19574395 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0009643 abnormal urine homeostasis PMID: 16400023 
Ar+|Artm4(AR)Dmr Artm4(AR)Dmr/Ar+
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0009643 abnormal urine homeostasis PMID: 16981011 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0004727 absent epididymis PMID: 7954809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0004727 absent epididymis PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0004727 absent epididymis PMID: 5452809 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0004727 absent epididymis PMID: 12943692 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0004727 absent epididymis PMID: 14745012 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0004727 absent epididymis PMID: 17317769 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0004727 absent epididymis PMID: 12370412 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0004727 absent epididymis PMID: 15107499 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009204 absent external male genitalia PMID: 12370412 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001159 absent prostate gland PMID: 12943692 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001159 absent prostate gland PMID: 16326839 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0001159 absent prostate gland PMID: 17317769 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001159 absent prostate gland PMID: 12370412 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0001159 absent prostate gland PMID: 15107499 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0002670 absent scrotum PMID: 17317769 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0003642 absent seminal vesicle PMID: 12943692 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0003642 absent seminal vesicle PMID: 14745012  15919750 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0003642 absent seminal vesicle PMID: 16326839 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0003642 absent seminal vesicle PMID: 17317769 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0003642 absent seminal vesicle PMID: 12370412 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0003642 absent seminal vesicle PMID: 15107499 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0003557 absent vas deferens PMID: 7954809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0003557 absent vas deferens PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0003557 absent vas deferens PMID: 5452809 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0003557 absent vas deferens PMID: 12943692 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0003557 absent vas deferens PMID: 14745012 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0003557 absent vas deferens PMID: 12370412 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0009073 absent Wolffian ducts PMID: 14745012 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0003448 altered tumor morphology PMID: 17406000 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0008261 arrest of male meiosis PMID: 5452809 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0008261 arrest of male meiosis PMID: 18401008 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0008261 arrest of male meiosis PMID: 14745012 
Artm1.1Reb Artm1.1Reb/Y
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2J		 MGI:88064  MP:0008261 arrest of male meiosis PMID: 14701682 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0008261 arrest of male meiosis PMID: 16326839 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0008261 arrest of male meiosis PMID: 17142319 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0008261 arrest of male meiosis PMID: 15107499  17142319 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0008261 arrest of male meiosis PMID: 17142319 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0008261 arrest of male meiosis PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0008261 arrest of male meiosis PMID: 18401008 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 7954809 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 12943692 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 14745012 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 16326839 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 12370412 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 15107499 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 17142319 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/Tg(Abpa-cre)1Cmal
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/0
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/Tg(AMH-cre)1Flor
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001155 arrest of spermatogenesis PMID: 19574395 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0005159 azoospermia PMID: 14745012 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0005159 azoospermia PMID: 14745012 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0005159 azoospermia PMID: 14701682 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0005159 azoospermia PMID: 16326839 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0005159 azoospermia PMID: 15107499  17142319 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0005159 azoospermia PMID: 17142319 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0003534 blind vagina PMID: 12943692 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0005608 cardiac interstitial fibrosis PMID: 15961403 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0009404 centrally nucleated skeletal muscle fibers PMID: 16981011 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0009238 coiled sperm flagellum PMID: 18356274 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0002286 cryptorchism PMID: 7954809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0002286 cryptorchism PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0002286 cryptorchism PMID: 5452809 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0002286 cryptorchism PMID: 12943692 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0002286 cryptorchism PMID: 14745012 
Artm1.1Reb Artm1.1Reb/Y
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2J		 MGI:88064  MP:0002286 cryptorchism PMID: 14701682 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0002286 cryptorchism PMID: 16326839 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0002286 cryptorchism PMID: 17317769 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002286 cryptorchism PMID: 12370412  17142319 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0002286 cryptorchism PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0002286 cryptorchism PMID: 18401008 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0004893 decreased adiponectin level PMID: 15919793 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001265 decreased body size PMID: 16981011 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001262 decreased body weight PMID: 16981011 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001262 decreased body weight PMID: 16326839 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001262 decreased body weight PMID: 12370412  15919793 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002790 decreased circulating follicle stimulating hormone level PMID: 16400023 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 16981011 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 16326839 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 17317769 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 12370412  15919793  17142319 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 15107499  17142319 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 15107499 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0002780 decreased circulating testosterone level PMID: 17142319 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0004929 decreased epididymis weight PMID: 14745012 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0004929 decreased epididymis weight PMID: 17360365 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0004929 decreased epididymis weight PMID: 17317769 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0002209 decreased germ cell number PMID: 17360365 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0010053 decreased grip strength PMID: 16981011 
Ar+|Artm4(AR)Dmr Artm4(AR)Dmr/Ar+
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0010053 decreased grip strength PMID: 16981011 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0002834 decreased heart weight PMID: 15961403 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0004502 decreased incidence of chemically-induced tumors PMID: 17406000 
Artm1.1Chc Artm1.1Chc/Artm1.1Chc
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0004502 decreased incidence of chemically-induced tumors PMID: 17406000 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0001935 decreased litter size PMID: 17360365 
Ar+|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Ar+,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001935 decreased litter size PMID: 12370412 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001935 decreased litter size PMID: 12370412 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0001935 decreased litter size PMID: 18356274 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0004901 decreased male germ cell number PMID: 14745012 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0004901 decreased male germ cell number PMID: 14745012 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0004901 decreased male germ cell number PMID: 16326839 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0004901 decreased male germ cell number PMID: 15107499 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0004856 decreased ovary weight PMID: 14676301 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009066 decreased oviduct weight PMID: 14676301 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0004962 decreased prostate gland weight PMID: 17360365 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0004962 decreased prostate gland weight PMID: 17317769 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0004910 decreased seminal vesicle weight PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0004910 decreased seminal vesicle weight PMID: 14701682 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0004910 decreased seminal vesicle weight PMID: 17360365 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0004910 decreased seminal vesicle weight PMID: 17317769 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0004910 decreased seminal vesicle weight PMID: 18356274 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0004852 decreased testis weight PMID: 14745012  15919750 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0004852 decreased testis weight PMID: 14745012  15919750 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0004852 decreased testis weight PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0004852 decreased testis weight PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0004852 decreased testis weight PMID: 16400023 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0004852 decreased testis weight PMID: 17360365 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0004852 decreased testis weight PMID: 16326839 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0004852 decreased testis weight PMID: 17317769 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0004852 decreased testis weight PMID: 15107499 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/0
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0004852 decreased testis weight PMID: 19574395 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/Tg(Abpa-cre)1Cmal
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0004852 decreased testis weight PMID: 19574395 
Artm1Jdz|Tg(Abpa-cre)1Cmal|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/0,Tg(AMH-cre)1Flor/0
involves: 129X1/SvJ * C57BL/6 * DBA/2 * SJL		 MGI:2450303  MGI:4431034  MGI:88064  MP:0004852 decreased testis weight PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/0
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0004852 decreased testis weight PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/Tg(AMH-cre)1Flor
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0004852 decreased testis weight PMID: 19574395 
Artm1Jdz|Tg(CMV-cre)1Cgn Artm1Jdz/Y,Tg(CMV-cre)1Cgn/0
involves: 129X1/SvJ * BALB/cJ		 MGI:2176179  MGI:88064  MP:0004852 decreased testis weight PMID: 19574395 
Artm3(AR)Dmr|Tg(TRAMP)8247Ng Artm3(AR)Dmr/Y,Tg(TRAMP)8247Ng/0
involves: 129S1/Sv * C57BL/6		 MGI:2680364  MGI:88064  MP:0002052 decreased tumor incidence PMID: 16601069 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0004905 decreased uterus weight PMID: 14676301 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0005598 decreased ventricle muscle contractility PMID: 15961403 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000539 distended urinary bladder PMID: 16981011 
Artm1Chc|Tg(Pbsn-cre)4Prb Artm1Chc/Y,Tg(Pbsn-cre)4Prb/0
involves: 129S/SvEv * C57BL/6 * DBA/2		 MGI:2388169  MGI:88064  MP:0004958 enlarged prostate gland PMID: 17652515 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0006308 enlarged seminiferous tubules PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0006308 enlarged seminiferous tubules PMID: 18401008 
Artm1.1Chc|Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Artm1.1Chc,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0000709 enlarged thymus PMID: 14676301 
ArTfm-Jms ArTfm-Jms/ArTfm-Jms
C57BL/6JJms		 MGI:88064  MP:0001926 female infertility PMID: 7967466 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0009243 hairpin sperm flagellum PMID: 18356274 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001559 hyperglycemia PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0003124 hypospadia PMID: 12370412 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0000242 impaired fertilization PMID: 18356274 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005293 impaired glucose tolerance PMID: 15919793 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0003157 impaired muscle relaxation PMID: 16981011 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0005565 increased blood urea nitrogen level PMID: 16981011 
Artm3(AR)Dmr Artm3(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001260 increased body weight PMID: 16601069 
Artm1(AR)Dmr Artm1(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001260 increased body weight PMID: 16601069 
ArTfm-Jms ArTfm-Jms/ArTfm-Jms
C57BL/6JJms		 MGI:88064  MP:0001260 increased body weight PMID: 7967466 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0005553 increased circulating creatinine level PMID: 16981011 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0001750 increased circulating follicle stimulating hormone level PMID: 14745012 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0001750 increased circulating follicle stimulating hormone level PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0001750 increased circulating follicle stimulating hormone level PMID: 14701682 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001750 increased circulating follicle stimulating hormone level PMID: 15107499 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005559 increased circulating glucose level PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0002079 increased circulating insulin level PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005669 increased circulating leptin level PMID: 15919793 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001751 increased circulating luteinizing hormone level PMID: 15919750 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0001751 increased circulating luteinizing hormone level PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0001751 increased circulating luteinizing hormone level PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001751 increased circulating luteinizing hormone level PMID: 16400023 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001751 increased circulating luteinizing hormone level PMID: 15107499 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0001751 increased circulating luteinizing hormone level PMID: 15107499 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0005117 increased circulating pituitary hormone level PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0005117 increased circulating pituitary hormone level PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0005627 increased circulating potassium level PMID: 16981011 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0002781 increased circulating testosterone level PMID: 14701682 
Artm1Reb|Tg(Amh-cre)8815Reb Artm1Reb/Y,Tg(Amh-cre)8815Reb/?
involves: 129S4/SvJaeSor * FVB/N		 MGI:3044682  MGI:88064  MP:0002781 increased circulating testosterone level PMID: 14701682 
Ar+|Artm4(AR)Dmr Artm4(AR)Dmr/Ar+
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002781 increased circulating testosterone level PMID: 16981011 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001552 increased circulating triglyceride level PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009285 increased gonadal fat pad weight PMID: 15919793 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0008214 increased immature B cell number PMID: 9647203 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009355 increased liver triglyceride level PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0004984 increased osteoclast cell number PMID: 12370412 
Artm3(AR)Dmr Artm3(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0005458 increased percent body fat PMID: 16601069 
Artm1(AR)Dmr Artm1(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0005458 increased percent body fat PMID: 16601069 
Artm1(AR)Dmr|Tg(TRAMP)8247Ng Artm1(AR)Dmr/Y,Tg(TRAMP)8247Ng/0
involves: 129S1/Sv * C57BL/6		 MGI:2680364  MGI:88064  MP:0010357 increased prostate gland tumor incidence PMID: 16601069 
Artm2(AR)Dmr|Tg(TRAMP)8247Ng Artm2(AR)Dmr/Y,Tg(TRAMP)8247Ng/0
involves: 129S1/Sv * C57BL/6		 MGI:2680364  MGI:88064  MP:0010357 increased prostate gland tumor incidence PMID: 16601069 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0009302 increased renal fat pad weight PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005455 increased susceptibility to weight gain PMID: 15919793 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0004851 increased testis weight PMID: 18401008 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005317 increased triglyceride level PMID: 15919793 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0009403 increased variability of skeletal muscle fiber size PMID: 16981011 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0000008 increased white adipose tissue amount PMID: 12943692 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0000008 increased white adipose tissue amount PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005331 insulin resistance PMID: 15919793 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0009237 kinked sperm flagellum PMID: 18356274 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0001152 Leydig cell hyperplasia PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0001152 Leydig cell hyperplasia PMID: 18401008 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0005536 Leydig cell hypoplasia PMID: 15919750 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0005536 Leydig cell hypoplasia PMID: 15919750 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0008280 male germ cell apoptosis PMID: 14745012 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0008280 male germ cell apoptosis PMID: 14745012 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001925 male infertility PMID: 15107499  17142319 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0001925 male infertility PMID: 17142319 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/0
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0001925 male infertility PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/0
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001925 male infertility PMID: 19574395 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0002789 male pseudohermaphroditism PMID: 7954809 
ArTfm|Insl3tm1Imad ArTfm/Y,Insl3tm1Imad/Insl3tm1Imad
involves: 129/Sv * CD-1 * STOCK Eda		 MGI:108427  MGI:88064  MP:0002789 male pseudohermaphroditism PMID: 10319319 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0002789 male pseudohermaphroditism PMID: 5452809 
Artm1.1Reb Artm1.1Reb/Y
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2J		 MGI:88064  MP:0002789 male pseudohermaphroditism PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000938 motor neuron degeneration PMID: 16981011 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000747 muscle weakness PMID: 16981011 
Ar+|Artm4(AR)Dmr Artm4(AR)Dmr/Ar+
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000747 muscle weakness PMID: 16981011 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000751 myopathy PMID: 16981011 
Artm1Fcl Artm1Fcl/Artm1Fcl
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0002169 no abnormal phenotype detected PMID: 17360365 
Artm1Jdz Artm1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0002169 no abnormal phenotype detected PMID: 16326839 
Artm1Chc Artm1Chc/Y
involves: 129S/SvEv * C57BL/6J		 MGI:88064  MP:0002169 no abnormal phenotype detected PMID: 12370412 
Artm1Rax Artm1Rax/Artm1Rax
involves: 129S/SvEv * C57BL/6J		 MGI:88064  MP:0002169 no abnormal phenotype detected PMID: 15294140 
Artm1Rax Artm1Rax/Y
involves: 129S/SvEv * C57BL/6J		 MGI:88064  MP:0002169 no abnormal phenotype detected PMID: 15294140 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001261 obese PMID: 12943692 
Artm1Reb Artm1Reb/Y
involves: 129S4/SvJaeSor		 MGI:88064  MP:0002687 oligozoospermia PMID: 14701682 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002687 oligozoospermia PMID: 16400023 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001732 postnatal growth retardation PMID: 12943692 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0002083 premature death PMID: 16981011 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0002009 preneoplasia PMID: 17406000 
Artm1.1Chc Artm1.1Chc/Artm1.1Chc
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0002009 preneoplasia PMID: 17406000 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0000748 progressive muscle weakness PMID: 16981011 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0001922 reduced male fertility PMID: 16400023  16981011 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0001922 reduced male fertility PMID: 17360365 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0001922 reduced male fertility PMID: 18356274 
Amhtm1Bhr|ArTfm Amhtm1Bhr/Amhtm1Bhr,ArTfm/Y
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)		 MGI:88006  MGI:88064  MP:0001939 secondary sex reversal PMID: 7954809 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0001939 secondary sex reversal PMID: 5452809 
ArTfm ArTfm/Y
involves: STOCK Eda Atp7a		 MGI:88064  MP:0001939 secondary sex reversal PMID: 18401008 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0001939 secondary sex reversal PMID: 12943692 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001939 secondary sex reversal PMID: 14745012 
Artm1.1Reb Artm1.1Reb/Y
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2J		 MGI:88064  MP:0001939 secondary sex reversal PMID: 14701682 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001939 secondary sex reversal PMID: 16326839 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0001939 secondary sex reversal PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0001939 secondary sex reversal PMID: 18401008 
ArTfm-Jms ArTfm-Jms/Y
C57BL/6JJms		 MGI:88064  MP:0001939 secondary sex reversal PMID: 7967466 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001154 seminiferous tubule degeneration PMID: 17142319 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0005250 Sertoli cell hypoplasia PMID: 17360365 
Artm1.1Jdz Artm1.1Jdz/Y
involves: 129X1/SvJ * C57BL/6		 MGI:88064  MP:0003550 short perineum PMID: 17317769 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0009413 skeletal muscle fiber atrophy PMID: 16981011 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0002188 small heart PMID: 15961403 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0004565 small myocardial fiber PMID: 15961403 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0005188 small penis PMID: 12370412 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0002774 small prostate gland PMID: 17317769 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0000664 small prostate gland anterior lobe PMID: 17317769 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: 129X1/SvJ * C57BL/6 * FVB/N		 MGI:3717411  MGI:88064  MP:0000661 small prostate gland ventral lobe PMID: 17317769 
Artm1Jdz|Tg(Pbsn-cre)20Fwan Artm1Jdz/Y,Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6J * FVB/N		 MGI:3717411  MGI:88064  MP:0001157 small seminal vesicle PMID: 18356274 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001153 small seminiferous tubules PMID: 14745012 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0001153 small seminiferous tubules PMID: 14745012 
Artm1Fcl Artm1Fcl/Y
involves: 129S2/SvPas * C57BL/6		 MGI:88064  MP:0001153 small seminiferous tubules PMID: 17360365 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001153 small seminiferous tubules PMID: 16326839 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001153 small seminiferous tubules PMID: 17142319 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0001153 small seminiferous tubules PMID: 17142319 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/0
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0001153 small seminiferous tubules PMID: 19574395 
Artm1Jdz|Tg(Abpa-cre)1Cmal Artm1Jdz/Y,Tg(Abpa-cre)1Cmal/Tg(Abpa-cre)1Cmal
involves: 129X1/SvJ * C57BL/6 * DBA/2		 MGI:4431034  MGI:88064  MP:0001153 small seminiferous tubules PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/0
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001153 small seminiferous tubules PMID: 19574395 
Artm1Jdz|Tg(AMH-cre)1Flor Artm1Jdz/Y,Tg(AMH-cre)1Flor/Tg(AMH-cre)1Flor
involves: 129X1/SvJ * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001153 small seminiferous tubules PMID: 19574395 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0001147 small testis PMID: 5452809 
Artm1.1Verh Artm1.1Verh/Y
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:88064  MP:0001147 small testis PMID: 14745012 
Artm1Verh|Tg(AMH-cre)1Flor Artm1Verh/Y,Tg(AMH-cre)1Flor/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6		 MGI:2450303  MGI:88064  MP:0001147 small testis PMID: 14745012 
Artm1.1Reb Artm1.1Reb/Y
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2J		 MGI:88064  MP:0001147 small testis PMID: 14701682 
Artm1.1Jdz Artm1.1Jdz/Y
B6.129X1-Ar		 MGI:88064  MP:0001147 small testis PMID: 16326839 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001147 small testis PMID: 17142319 
Artm1Chc|Tg(AMH-cre)1Flor Artm1Chc/Y,Tg(AMH-cre)1Flor/0
involves: 129S/SvEv * C57BL/6 * SJL		 MGI:2450303  MGI:88064  MP:0001147 small testis PMID: 17142319 
Artm1.1Chc Artm1.1Chc/Y
involves: 129S/SvEv * C57BL/6 * FVB/N		 MGI:88064  MP:0001147 small testis PMID: 15107499 
Amhr2+|Amhr2tm3(cre)Bhr|Artm1Chc Amhr2tm3(cre)Bhr/Amhr2+,Artm1Chc/Y
involves: 129S/SvEv * C57BL/6		 MGI:105062  MGI:88064  MP:0001147 small testis PMID: 17142319 
ArTfm-Jms ArTfm-Jms/Y
C57BL/6JJms		 MGI:88064  MP:0001147 small testis PMID: 7967466 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0003205 testicular atrophy PMID: 12943692 
Artm4(AR)Dmr Artm4(AR)Dmr/Y
involves: 129S1/Sv * C57BL/6J		 MGI:88064  MP:0003205 testicular atrophy PMID: 16400023  16981011 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0003205 testicular atrophy PMID: 15919793 
Artm1Chc|Tg(ACTB-cre)2Mrt Artm1Chc/Y,Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6J * FVB/N		 MGI:2176049  MGI:88064  MP:0001940 testicular hypoplasia PMID: 12370412 
ArTfm|Tg(TSPY)9Jshm ArTfm/Y,Tg(TSPY)9Jshm/0
involves: NMRI * STOCK Eda Atp7a		 MGI:3775643  MGI:88064  MP:0006262 testis tumor PMID: 18401008 
ArTfm ArTfm/Y
involves: NMRI * STOCK Eda Atp7a		 MGI:88064  MP:0006262 testis tumor PMID: 18401008 
Artm1Ska|Tg(CMV-cre)1Ipc Artm1Ska/Y,Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA		 MGI:2177164  MGI:88064  MP:0000280 thin ventricular wall PMID: 15961403 
ArTfm ArTfm/Y
STOCK Eda Atp7a/+ +		 MGI:88064  MP:0001144 vagina atresia PMID: 5452809 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  46,XX sex reversal 1; SRXX1
Disease Ontology: DOID:14450
OMIM: 400045
Disease:  Androgen insensitivity syndrome; AIS
Synonyms: Complete androgen insensitivity syndrome [Orphanet: ORPHA99429]
Disease Ontology: DOID:4674
OMIM: 300068, 300274
Orphanet: ORPHA99429
Comments:  Transient transfection analysis of several AR mutations identified in AIS patients indicates that these mutations perturb AR ligand binding, DNA binding, or nuclear localization. Alteration at the receptor level: mutated
References:  14,51
Disease:  Hypospadias 1, X-linked; HYSP1
Synonyms: Familial hypospadia [Orphanet: ORPHA440]
Disease Ontology: DOID:10892
OMIM: 300633
Orphanet: ORPHA440
Disease:  Klinefelter syndrome
Synonyms: Klinefelter's syndrome [Disease Ontology: DOID:1921]
Disease Ontology: DOID:1921
Orphanet: ORPHA484
Comments:  Klinefelter syndrome (47, XXY - hypogonadism) is the most common chromosome aneuploidy in men and is usually characterized by underdeveloped testes and sterility. Skewed inactivation of the X-chromosome appears to contribute by reducing AR expression.
References:  39,47
Disease:  Partial androgen insensitivity syndrome
Disease Ontology: DOID:4674
OMIM: 312300
Orphanet: ORPHA90797
Disease:  Prostate cancer
Disease Ontology: DOID:10283
OMIM: 176807
Comments:  Mutations of AR affecting ligand binding as well as gene amplification of AR have been described. Alteration at the receptor level: sometimes increased. Alternative splice variants have been shown to play a role in castration resistant prostate cancer.
References:  3,17,54
Disease:  Spinal and bulbar muscular atrophy, X-linked 1; SMAX1
Synonyms: Kennedy disease [Orphanet: ORPHA481]
Kennedy's disease [Disease Ontology: DOID:0060161]
Disease Ontology: DOID:0060161
OMIM: 313200
Orphanet: ORPHA481
Comments:  Spinobulbar muscular atrophy (SBMA) is an X-linked form of motor neuron disease characterized by progressive atrophy of the muscles, dysphagia, dysarthria and mild androgen insensitivity. SMBA is caused by CAG repeat expansion in the androgen receptor gene.
References:  57,69,79
Biologically Significant Variants Click here for help
Type:  Alternative initiation of translation
Species:  Human
Description:  AR-A. N-terminally truncated androgen receptor isoform; 87 kDa
References:  94-95
Type:  Splice variant
Species:  Human
Description:  ARv567es. Androgen receptor isoform lacking exons 5, 6, and 7. More information on this protein can be found in the GenBank entry ACZ81436
References:  78
Type:  Splice variant
Species:  Human
Description:  AR-V7 (AR3). Androgen receptor isoform lacking exons 4-8 and has 16 unique amino acids from cryptic exon 3b. More information on this protein can be found in the GenBank entry ACN39559
References:  30,37
Type:  Splice variant
Species:  Human
Description:  Androgen receptor isoform 2 (AR45): 110 kda; lacks exon 1.
Amino acids:  388
Nucleotide accession:  NM_001011645
Protein accession:  NP_001011645
References:  1
General Comments
For more details on Androgen Receptor gene mutations please see The Androgen Receptor Gene Mutations Database.

References

Show »

1. Ahrens-Fath I, Politz O, Geserick C, Haendler B. (2005) Androgen receptor function is modulated by the tissue-specific AR45 variant. FEBS J, 272 (1): 74-84. [PMID:15634333]

2. Akita K, Harada K, Ichihara J, Takata N, Takahashi Y, Saito K. (2013) A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate. Eur J Pharmacol, 720 (1-3): 107-14. [PMID:24177288]

3. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL et al.. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med, 371 (11): 1028-38. [PMID:25184630]

4. Auerbach SS. DrugMatrix in vitro pharmacology data. Accessed on 30/04/2019. Modified on 30/04/2019. National Toxicology Program, https://ntp.niehs.nih.gov/drugmatrix/index.html

5. Bentvelsen FM, McPhaul MJ, Wilson CM, Wilson JD, George FW. (1996) Regulation of immunoreactive androgen receptor in the adrenal gland of the adult rat. Endocrinology, 137 (7): 2659-63. [PMID:8770883]

6. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP. (1998) High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol, 18 (8): 4471-87. [PMID:9671457]

7. Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French FS, Willard HF. (1989) Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet, 44 (2): 264-9. [PMID:2563196]

8. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES et al.. (2006) Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA, 103 (7): 2190-5. [PMID:16461912]

9. Casimiro-Garcia A, Piotrowski DW, Ambler C, Arhancet GB, Banker ME, Banks T, Boustany-Kari CM, Cai C, Chen X, Eudy R et al.. (2014) Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. J Med Chem, 57 (10): 4273-88. [PMID:24738581]

10. Chamness GC, Asch RH, Pauerstein CJ. (1980) Danazol binding and translocation of steroid receptors. Am J Obstet Gynecol, 136 (4): 426-9. [PMID:7355922]

11. Chan KK, Tsui SK, Ngai SM, Lee SM, Kotaka M, Waye MM, Lee CY, Fung KP. (2000) Protein-protein interaction of FHL2, a LIM domain protein preferentially expressed in human heart, with hCDC47. J Cell Biochem, 76 (3): 499-508. [PMID:10649446]

12. Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, Guillou F, Lardy H, Yeh S. (2004) Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc Natl Acad Sci USA, 101 (18): 6876-81. [PMID:15107499]

13. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. (2002) Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol, 16 (7): 1492-501. [PMID:12089345]

14. Choong CS, Sturm MJ, Strophair JA, McCulloch RK, Hurley DM. (1997) Reduced expression and normal nucleotide sequence of androgen receptor gene coding and promoter regions in a family with partial androgen insensitivity syndrome. Clin Endocrinol (Oxf), 46 (3): 281-8. [PMID:9156036]

15. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem, 271 (11): 6379-88. [PMID:8626436]

16. Coulthard VH, Matsuda S, Heery DM. (2003) An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. J Biol Chem, 278 (13): 10942-51. [PMID:12556447]

17. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J et al.. (2015) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol, 67 (1): 53-60. [PMID:24882673]

18. Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H. (2005) Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes, 54 (4): 1000-8. [PMID:15793238]

19. Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, Sheehan DM. (2003) Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol, 16 (10): 1338-58. [PMID:14565775]

20. Ferraboschi P, Legnani L, Celasco G, Moro L, Ragonesi L, Colombo D. (2014) A full conformational characterization of antiandrogen cortexolone-17-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopy. MedChemComm, 5: 904-914. DOI: 10.1039/C4MD00049H

21. Francke U, Taggart RT. (1980) Comparative gene mapping: order of loci on the X chromosome is different in mice and humans. Proc Natl Acad Sci USA, 77 (6): 3595-9. [PMID:6251472]

22. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem, 275 (27): 20853-60. [PMID:10779504]

23. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C. (1999) Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem, 274 (12): 8316-21. [PMID:10075738]

24. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem, 277 (29): 25904-13. [PMID:11994312]

25. Georget V, Térouanne B, Nicolas JC, Sultan C. (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry, 41 (39): 11824-31. [PMID:12269826]

26. Geserick C, Meyer HA, Barbulescu K, Haendler B. (2003) Differential modulation of androgen receptor action by deoxyribonucleic acid response elements. Mol Endocrinol, 17 (9): 1738-50. [PMID:12791770]

27. Giwercman A, Kledal T, Schwartz M, Giwercman YL, Leffers H, Zazzi H, Wedell A, Skakkebaek NE. (2000) Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene. J Clin Endocrinol Metab, 85 (6): 2253-9. [PMID:10852459]

28. Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S. (2013) Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate, 73 (12): 1291-305. [PMID:23765603]

29. Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M et al.. (2011) Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem, 54 (21): 7693-704. [PMID:21936524]

30. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG et al.. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res, 69 (6): 2305-13. [PMID:19244107]

31. Haelens A, Verrijdt G, Callewaert L, Peeters B, Rombauts W, Claessens F. (2001) Androgen-receptor-specific DNA binding to an element in the first exon of the human secretory component gene. Biochem J, 353 (Pt 3): 611-20. [PMID:11171058]

32. Hamann LG, Higuchi RI, Zhi L, Edwards JP, Wang XN, Marschke KB, Kong JW, Farmer LJ, Jones TK. (1998) Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J Med Chem, 41 (4): 623-39. [PMID:9484511]

33. Han X, Zhao L, Xiang W, Qin C, Miao B, Xu T, Wang M, Yang CY, Chinnaswamy K, Stuckey J et al.. (2019) Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem, 62 (24): 11218-11231. [PMID:31804827]

34. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman Jr D, Farquhar R, Guo Z, Qiu Y et al.. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem, 48 (8): 2972-84. [PMID:15828836]

35. Higuchi RI, Arienti KL, López FJ, Mani NS, Mais DE, Caferro TR, Long YO, Jones TK, Edwards JP, Zhi L et al.. (2007) Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem, 50 (10): 2486-96. [PMID:17439112]

36. Hsiao PW, Lin DL, Nakao R, Chang C. (1999) The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem, 274 (29): 20229-34. [PMID:10400640]

37. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB et al.. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res, 69 (1): 16-22. [PMID:19117982]

38. Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J, Chang C. (2004) Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem, 279 (32): 33438-46. [PMID:15166229]

39. Iitsuka Y, Bock A, Nguyen DD, Samango-Sprouse CA, Simpson JL, Bischoff FZ. (2001) Evidence of skewed X-chromosome inactivation in 47,XXY and 48,XXYY Klinefelter patients. Am J Med Genet, 98 (1): 25-31. [PMID:11426451]

40. Ito K, Adachi S, Iwakami R, Yasuda H, Muto Y, Seki N, Okano Y. (2001) N-Terminally extended human ubiquitin-conjugating enzymes (E2s) mediate the ubiquitination of RING-finger proteins, ARA54 and RNF8. Eur J Biochem, 268 (9): 2725-32. [PMID:11322894]

41. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J. (2010) Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem, 53 (7): 2779-96. [PMID:20218717]

42. Kang HY, Yeh S, Fujimoto N, Chang C. (1999) Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem, 274 (13): 8570-6. [PMID:10085091]

43. Kang Z, Pirskanen A, Jänne OA, Palvimo JJ. (2002) Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem, 277 (50): 48366-71. [PMID:12376534]

44. Kerkhofs S, Dubois V, De Gendt K, Helsen C, Clinckemalie L, Spans L, Schuit F, Boonen S, Vanderschueren D, Saunders PT et al.. (2012) A role for selective androgen response elements in the development of the epididymis and the androgen control of the 5α reductase II gene. FASEB J, 26 (10): 4360-72. [PMID:22798427]

45. Khan OY, Fu G, Ismail A, Srinivasan S, Cao X, Tu Y, Lu S, Nawaz Z. (2006) Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol, 20 (3): 544-59. [PMID:16254014]

46. Kinoyama I, Taniguchi N, Toyoshima A, Nozawa E, Kamikubo T, Imamura M, Matsuhisa A, Samizu K, Kawanimani E, Niimi T et al.. (2006) (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist. J Med Chem, 49 (2): 716-26. [PMID:16420057]

47. Kotula-Balak M, Bablok L, Fracki S, Jankowska A, Bilińska B. (2004) Immunoexpression of androgen receptors and aromatase in testes of patient with Klinefelter's syndrome. Folia Histochem Cytobiol, 42 (4): 215-20. [PMID:15704647]

48. Krieg M, Dennis M, Voigt KD. (1976) Comparison between the binding of 19-nortestosterone, 5alpha-dihydrotestosterone and testosterone in rat prostate and bulbocavernosus/levator ani muscle. J Endocrinol, 70 (3): 379-87. [PMID:978099]

49. Lee IR, Dawson SA, Wetherall JD, Hahnel R. (1987) Sex hormone-binding globulin secretion by human hepatocarcinoma cells is increased by both estrogens and androgens. J Clin Endocrinol Metab, 64 (4): 825-31. [PMID:3029159]

50. Li JJ, Iula DM, Nguyen MN, Hu LY, Dettling D, Johnson TR, Du DY, Shanmugasundaram V, Van Camp JA, Wang Z et al.. (2008) Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications. J Med Chem, 51 (21): 7010-4. [PMID:18921992]

51. Liegibel UM, Sommer U, Boercsoek I, Hilscher U, Bierhaus A, Schweikert HU, Nawroth P, Kasperk C. (2003) Androgen receptor isoforms AR-A and AR-B display functional differences in cultured human bone cells and genital skin fibroblasts. Steroids, 68 (14): 1179-87. [PMID:14643880]

52. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS. (1999) Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res, 59 (17): 4180-4. [PMID:10485450]

53. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. (2005) Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes, 54 (6): 1717-25. [PMID:15919793]

54. Linja MJ, Visakorpi T. (2004) Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol, 92 (4): 255-64. [PMID:15663988]

55. Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S. (2013) AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia, 15 (9): 1009-17. [PMID:24027426]

56. Lyon MF, Hawkes SG. (1970) X-linked gene for testicular feminization in the mouse. Nature, 227 (5264): 1217-9. [PMID:5452809]

57. MacLean HE, Choi WT, Rekaris G, Warne GL, Zajac JD. (1995) Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy). J Clin Endocrinol Metab, 80 (2): 508-16. [PMID:7852512]

58. Majumder S, Liu Y, Ford 3rd OH, Mohler JL, Whang YE. (2006) Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate, 66 (12): 1292-301. [PMID:16705743]

59. Manfredi MC, Bi Y, Nirschl AA, Sutton JC, Seethala R, Golla R, Beehler BC, Sleph PG, Grover GJ, Ostrowski J et al.. (2007) Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators. Bioorg Med Chem Lett, 17 (16): 4487-90. [PMID:17574413]

60. Marivoet S, Van Dijck P, Verhoeven G, Heyns W. (1992) Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Mol Cell Endocrinol, 88 (1-3): 165-74. [PMID:1459337]

61. Maruyama K, Nakamura M, Tomoshige S, Sugita K, Makishima M, Hashimoto Y, Ishikawa M. (2013) Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERα-selective antagonist. Bioorg Med Chem Lett, 23 (14): 4031-6. [PMID:23768907]

62. McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW. (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol, 69 (1-6): 3-12. [PMID:10418975]

63. Mestayer C, Blanchère M, Jaubert F, Dufour B, Mowszowicz I. (2003) Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate, 56 (3): 192-200. [PMID:12772188]

64. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C. (2002) A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem, 277 (7): 4609-17. [PMID:11673464]

65. Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, Kitamura H, Kubota Y. (2003) Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate, 56 (4): 280-6. [PMID:12858356]

66. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD. (2009) Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem, 52 (12): 3597-617. [PMID:19432422]

67. Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ, Kallio PJ. (2015) Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep, 5: 12007. [PMID:26137992]

68. Müller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schüle R. (2000) FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J, 19 (3): 359-69. [PMID:10654935]

69. Neuschmid-Kaspar F, Gast A, Peterziel H, Schneikert J, Muigg A, Ransmayr G, Klocker H, Bartsch G, Cato AC. (1996) CAG-repeat expansion in androgen receptor in Kennedy's disease is not a loss of function mutation. Mol Cell Endocrinol, 117 (2): 149-56. [PMID:8737374]

70. Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL. (2004) Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocr Relat Cancer, 11 (1): 117-30. [PMID:15027889]

71. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS. (1993) Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol, 7 (1): 23-36. [PMID:8446105]

72. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Jänne OA, Palvimo JJ, Pestell RG. (2001) Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol, 15 (5): 797-811. [PMID:11328859]

73. Saartok T, Dahlberg E, Gustafsson JA. (1984) Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology, 114 (6): 2100-6. [PMID:6539197]

74. Scheller A, Scheinman RI, Thompson E, Scarlett CO, Robins DM. (1996) Contextual dependence of steroid receptor function on an androgen-responsive enhancer. Mol Cell Endocrinol, 121 (1): 75-86. [PMID:8865168]

75. Shang Y, Myers M, Brown M. (2002) Formation of the androgen receptor transcription complex. Mol Cell, 9 (3): 601-10. [PMID:11931767]

76. Simard J, Singh SM, Labrie F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology, 49 (4): 580-6; discussion 586-9. [PMID:9111629]

77. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD et al.. (2014) Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem, 289 (3): 1529-39. [PMID:24297183]

78. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al.. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest, 120 (8): 2715-30. [PMID:20644256]

79. Sułek A, Hoffman-Zacharska D, Krysa W, Szirkowiec W, Fidziańska E, Zaremba J. (2005) CAG repeat polymorphism in the androgen receptor (AR) gene of SBMA patients and a control group. J Appl Genet, 46 (2): 237-9. [PMID:15876692]

80. Takeda H, Chodak G, Mutchnik S, Nakamoto T, Chang C. (1990) Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor. J Endocrinol, 126 (1): 17-25. [PMID:2199591]

81. Tan JA, Joseph DR, Quarmby VE, Lubahn DB, Sar M, French FS, Wilson EM. (1988) The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol, 2 (12): 1276-85. [PMID:3216867]

82. Tan JA, Marschke KB, Ho KC, Perry ST, Wilson EM, French FS. (1992) Response elements of the androgen-regulated C3 gene. J Biol Chem, 267 (7): 4456-66. [PMID:1537831]

83. Teller MN, Stock CC, Bowie M, Chou TC, Budinger JM. (1982) Therapy of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas with combinations of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate. Cancer Res, 42 (11): 4408-12. [PMID:6812946]

84. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. (1989) Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA, 86 (1): 327-31. [PMID:2911578]

85. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al.. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310 (5748): 644-8. [PMID:16254181]

86. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al.. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324 (5928): 787-90. [PMID:19359544]

87. van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Trapman J, Jenster G. (2009) Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression. Mol Endocrinol, 23 (11): 1776-86. [PMID:19762545]

88. Verrijdt G, Haelens A, Schoenmakers E, Rombauts W, Claessens F. (2002) Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors. Biochem J, 361 (Pt 1): 97-103. [PMID:11742533]

89. Verrijdt G, Schoenmakers E, Alen P, Haelens A, Peeters B, Rombauts W, Claessens F. (1999) Androgen specificity of a response unit upstream of the human secretory component gene is mediated by differential receptor binding to an essential androgen response element. Mol Endocrinol, 13 (9): 1558-70. [PMID:10478846]

90. von Geldern TW, Tu N, Kym PR, Link JT, Jae HS, Lai C, Apelqvist T, Rhonnstad P, Hagberg L, Koehler K et al.. (2004) Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem, 47 (17): 4213-30. [PMID:15293993]

91. Wakabayashi K, Imai K, Miyachi H, Hashimoto Y, Tanatani A. (2008) 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor. Bioorg Med Chem, 16 (14): 6799-812. [PMID:18571420]

92. Wang LG, Liu XM, Kreis W, Budman DR. (1998) Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol, 55 (9): 1427-33. [PMID:10076535]

93. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell, 27 (3): 380-92. [PMID:17679089]

94. Wilson CM, McPhaul MJ. (1994) A and B forms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci USA, 91 (4): 1234-8. [PMID:8108393]

95. Wilson CM, McPhaul MJ. (1996) A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol, 120 (1): 51-7. [PMID:8809738]

96. Ye X, Han SJ, Tsai SY, DeMayo FJ, Xu J, Tsai MJ, O'Malley BW. (2005) Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc Natl Acad Sci USA, 102 (27): 9487-92. [PMID:15983373]

97. Yeh S, Sampson ER, Lee DK, Kim E, Hsu CL, Chen YL, Chang HC, Altuwaijri S, Huang KE, Chang C. (2000) Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer. J Formos Med Assoc, 99 (12): 885-94. [PMID:11155740]

98. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. (2003) Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther, 304 (3): 1334-40. [PMID:12604714]

99. Yong W, Yang Z, Periyasamy S, Chen H, Yucel S, Li W, Lin LY, Wolf IM, Cohn MJ, Baskin LS et al.. (2007) Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J Biol Chem, 282 (7): 5026-36. [PMID:17142810]

100. Zhang S, Murtha PE, Young CY. (1997) Defining a functional androgen responsive element in the 5' far upstream flanking region of the prostate-specific antigen gene. Biochem Biophys Res Commun, 231 (3): 784-8. [PMID:9070893]

101. Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T et al.. (2021) Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). J Med Chem, 64 (2): 909-924. [PMID:33470111]

102. Zhou T, Xu W, Zhang W, Sun Y, Yan H, Gao X, Wang F, Zhou Q, Hou J, Ren S et al.. (2020) Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer. Eur J Cancer, 134: 29-40. [PMID:32460179]

103. Zhou XE, Suino-Powell KM, Li J, He Y, Mackeigan JP, Melcher K, Yong EL, Xu HE. (2010) Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J Biol Chem, 285 (12): 9161-71. [PMID:20086010]

104. Zierau O, Kolodziejczyk A, Vollmer G, Machalz D, Wolber G, Thieme D, Keiler AM. (2019) Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay. J Steroid Biochem Mol Biol, 189: 81-86. [PMID:30825507]

Contributors

Show »

How to cite this page